Skip to main content

Table 3 Logistic regression models of non-persistence of DMARD

From: Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort

Variable

Categories

Risk of change

Reasons for changing DMARD

Risk of adverse drug reaction

Risk of lack of efficacy

Female gender

Y/N

1.11 (0.69 - 1.80)

1.52 (0.81 – 2.85)

1.20 (0.71 – 2.03)

Age

Quartiles

0.89 (0.72 - 1.10)

1.23 (0.94 – 1.60)

0.69 (0.55 – 0.87) **

Ever smoked

Y/N

1.38 (0.89 - 2.15)

1.29 (0.59 – 2.78)

1.35 (0.83 – 2.19)

DAS28

EULAR categories

1.12 (0.78 - 1.62)

0.95 (0.58 – 1.57)

1.29 (0.83 – 2.02)

>4 of 1987 ACR criteria

Y/N

0.98 (0.59 – 1.65)

1.04 (0.57 – 1.91)

1.20 (0.72 – 2.01)

Extra-articular disease

Y/N

1.78 (1.00 - 3.16) *

1.29 (0.59 – 2.78)

2.27 (1.25 – 4.11) **

Co-morbidities

Y/N

1.02 (0.66 - 1.57)

1.18 (0.67 – 2.09)

0.82 (0.51 – 1.32)

HAQ score

Quartiles

1.44 (1.12 - 1.86) **

1.10 (0.80 – 1.52)

1.36 (1.03 – 1.81) *

SF36-bodily pain

Quartiles

0.93 (0.72 - 1.19)

1.03 (0.75 – 1.43)

1.18 (0.90 – 1.55)

SF36-mental health

Quartiles

1.44 (1.16 - 1.78) **

1.43 (1.08 – 1.89) *

1.22 (0.97 – 1.52)

DAS28-P

Quartiles

1.09 (0.88 - 1.35)

1.04 (0.79 – 1.37)

1.10 (0.86 – 1.41)

SSZ monotherapy

Y/N

1.09 (0.57 - 2.12)

1.92 (0.85 – 4.37)

0.74 (0.35 – 1.54)

MTX monotherapy

Y/N

0.56 (0.29 - 1.06)

0.38 (0.16 – 0.94) *

0.57 (0.28 – 1.17)

MTX + SSZ + HCQ

Y/N

0.30 (0.12 - 0.79) *

0.33 (0.08 – 1.38)

0.14 (0.04 – 0.53) **

  1. Variables associated with a non-persistence of DMARD treatment within the first 2 years in the ERAN cohort (428 people had data analysed). Adjusted odds ratios (95% confidence intervals). * = p < 0.05, ** = p < 0.01. Statistically significant results are presented in bold.